Welcome to our dedicated page for Rigel Pharmaceuticals (New) news (Ticker: RIGL), a resource for investors and traders seeking the latest updates and insights on Rigel Pharmaceuticals (New) stock.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a leading biotechnology company based in South San Francisco, California, dedicated to discovering, developing, and providing novel therapies that significantly improve the lives of patients with immune and hematologic disorders, cancer, and rare diseases. Established in 1996, Rigel has built a solid reputation in the pharmaceutical industry by focusing on the development of small-molecule drugs.
The company's flagship product, TAVALISSE (fostamatinib disodium hexahydrate) tablets, is the only oral spleen tyrosine kinase (SYK) inhibitor approved for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
REZLIDHIA (olutasidenib), another key product, is an oral small-molecule inhibitor of mutant isocitrate dehydrogenase-1 (mIDH1), indicated for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible IDH1 mutation.
Rigel's pipeline includes a variety of promising candidates such as R289, an IRAK1/4 dual inhibitor for the treatment of lower-risk myelodysplastic syndrome (LR-MDS), R552, R835, THF-beta Inhibitors, and AZD0449 - an inhaled JAK inhibitor. The company is also exploring the potential of olutasidenib in high-grade glioma (HGG) through a collaboration with CONNECT, an international network of pediatric cancer centers.
Recent financial highlights include a reported net product sales of $104.3 million in 2023, showcasing a significant growth of 36% over the previous year. Rigel's partnership with major pharmaceutical companies like AstraZeneca for their rheumatoid arthritis drug and Grifols S.A. for delivery of drug supplies reinforces their strong market position.
In 2024, Rigel announced the acquisition of U.S. rights to GAVRETO (pralsetinib), a kinase inhibitor approved for treating metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and advanced or metastatic RET fusion-positive thyroid cancer. This acquisition aligns with Rigel's strategy to expand its hematology and oncology portfolio, leveraging its existing commercial infrastructure.
Rigel continues to focus on commercial execution, strategic collaborations, and advancing its robust pipeline to reach financial breakeven and deliver transformative treatments to underserved patient populations.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced the grant of stock options totaling 469,000 shares to 23 new employees, approved by its Compensation Committee. These options, priced at $3.52 per share, vest over four years and were granted under the company's Inducement Plan following NASDAQ Listing Rule 5635(c)(4). Rigel focuses on developing novel small molecule drugs targeting hematologic disorders, cancer, and rare immune diseases. It also conducts several clinical trials, including studies for its first FDA-approved product, TAVALISSE, in various indications.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced participation in several virtual investor conferences in September 2021. CEO Raul Rodriguez will speak on a panel at Citi's 16th Annual Biopharma Conference on September 10, focusing on advancements in benign hematology. CFO Dean Schorno will present a company overview at the H.C. Wainwright Annual Global Investment Conference, available from September 13. Additionally, Rodriguez will present at the Cantor Fitzgerald Global Healthcare Conference on September 28. Details and webcasts can be found on Rigel's investor relations website.
Rigel Pharmaceuticals (Nasdaq: RIGL) announced the publication of Phase 2 clinical trial results for fostamatinib in treating hospitalized COVID-19 patients. Conducted in collaboration with NIH's NHLBI, the trial involved 59 patients and showed that fostamatinib, when added to standard care, led to fewer serious adverse events and improved clinical outcomes. Key findings indicated a reduction in mortality rates, ICU stay duration, and time on supplemental oxygen compared to placebo. A larger Phase 3 trial is set to further validate these findings.
Rigel Pharmaceuticals (Nasdaq: RIGL) announced that the FDA deemed clinical data from a Phase 2 trial of fostamatinib insufficient for emergency use authorization in treating hospitalized COVID-19 patients. Despite this setback, the FDA expressed willingness to collaborate on the development of fostamatinib, as Rigel pursues a larger Phase 3 trial involving 308 patients. The primary endpoint is to assess progression to severe disease within 29 days. Current enrollment is at approximately 176 patients, anticipated to conclude by year-end.
Rigel Pharmaceuticals (Nasdaq: RIGL) reported its Q2 2021 financial results, revealing total revenues of $26.3 million, primarily from TAVALISSE sales, which increased 14% year-over-year. The company incurred a net loss of $13.8 million, an improvement from the prior year's loss. Rigel is expanding its sales force from 39 to 55 territories and is advancing its pipeline, including a Phase 3 trial of fostamatinib in COVID-19 patients. Cash and equivalents reached $153.4 million as of June 30, 2021.
Rigel Pharmaceuticals will announce its Q2 2021 financial results on August 3, 2021, after market close. A conference call will follow at 4:30 PM ET for a business update. Investors can access the call at 877-407-3088 (domestic) or 201-389-0927 (international). Rigel specializes in developing small molecule drugs for hematologic disorders, cancer, and rare immune diseases, with its first product, TAVALISSE, approved by the FDA for chronic immune thrombocytopenia.
Rigel Pharmaceuticals (Nasdaq: RIGL) announced that data from its clinical program for TAVALISSE (fostamatinib) will be presented at the ISTH Virtual Congress from July 17-21, 2021. Key findings reveal that long-term treatment with TAVALISSE results in increased platelet counts in patients with immune thrombocytopenia (ITP), with a 91% response rate after a year. Additionally, the need for rescue therapy decreased over time. TAVALISSE is the first SYK inhibitor approved for chronic ITP, helping patients with inadequate responses to previous therapies.
Rigel Pharmaceuticals (RIGL) announced that its oral spleen tyrosine kinase inhibitor, fostamatinib, has been selected for inclusion in the NIH ACTIV-4 trial, targeting COVID-19 treatment in hospitalized patients. This landmark trial aims to assess therapies that protect and heal host tissues affected by the virus. Previous Phase 2 studies indicated positive outcomes for fostamatinib, meeting primary safety endpoints and improving efficacy in mortality and ICU days. The trial will involve approximately 300 patients in a randomized and placebo-controlled setup.
Rigel Pharmaceuticals (Nasdaq: RIGL) announced that CEO Raul Rodriguez will present a company overview on June 2, 2021, at the Jefferies Virtual Healthcare Conference at 1:00 p.m. Eastern Time. Investors can access the live and archived webcast on Rigel's website.
Rigel focuses on developing innovative treatments for hematologic disorders, cancer, and rare immune diseases. Its FDA-approved product, TAVALISSE, treats chronic immune thrombocytopenia. The company is also conducting various clinical trials, including those for COVID-19.
Rigel Pharmaceuticals (Nasdaq: RIGL) announced the appointment of Dr. Alison L. Hannah to its Board of Directors. With over 30 years of experience in the pharmaceutical sector, she specializes in clinical development strategy for hematology and oncology, focusing on molecularly targeted therapies. Dr. Hannah has contributed to the regulatory approval of over 40 cancer treatments and served in key roles at various biotech firms. Her expertise is expected to enhance Rigel's clinical development initiatives as the company advances its hematology, immunology, and oncology programs.
FAQ
What is the current stock price of Rigel Pharmaceuticals (New) (RIGL)?
What is the market cap of Rigel Pharmaceuticals (New) (RIGL)?
What is Rigel Pharmaceuticals' core business?
What are Rigel's primary products?
What recent acquisitions has Rigel made?
Who are Rigel's key partners?
What are some of Rigel's pipeline products?
Where is Rigel Pharmaceuticals headquartered?
What financial milestones did Rigel achieve in 2023?
What is the significance of REZLIDHIA?
What collaborations is Rigel involved in for pediatric cancer?
What is the market focus for TAVALISSE?
